All In Biotech

Drug Trial Radar · NCT05003531

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

A Phase II Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jan 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

250

Actual

Start

Sep 23, 2021

Primary completion

Mar 25, 2022

Study completion Jan 17, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of IBI112 administered in different dose regimens for the treatment of patients with plaque psoriasis

Conditions

  • Psoriasis

Interventions

  • IBI112 dose 2Drug

    Participants will receive placebo or dose 2 IBI112 SC

  • IBI112 dose 4Drug

    Participants will receive placebo or dose 4 IBI112 SC

  • IBI112 dose 1Drug

    Participants will receive placebo or dose 1 IBI112 SC

  • IBI112 dose 3Drug

    Participants will receive placebo or dose 3 IBI112 SC

  • placeboDrug

    Participants will receive placebo SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients achieving Psoriasis Area and severity index(PASI) 90 at week 16Time frame: Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PeKing University People's Hostpital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.